Table 1 Main characteristics of patients at golimumab initiation
All (n = 125) | RA (n = 72) | Axial SpA (n = 23) | PsA (n = 30) | |
|---|---|---|---|---|
Mean age, years (SD) | 55.9 (13.5) | 61.5 (12.2) | 50.8 (12.7) | 46.7 (10.3) |
Gender, n (%) | ||||
Male | 40 (32.0) | 10 (13.9) | 16 (69.6) | 14 (46.7) |
Female | 85 (68.0) | 62 (86.1) | 7 (30.4) | 16 (53.3) |
Median disease duration, years (IQR) | 10.0 (6.5–17.4) | 10.6 (7.6–18.6) | 10.4 (5.7–44.0) | 8.7 (4.6–10.9) |
Order (line) of golimumab therapy, n (%) | ||||
Second | 26 (20.8) | 15 (20.8) | 2 (8.7) | 9 (30.0) |
Third | 29 (23.2) | 14 (19.4) | 9 (39.1) | 6 (20.0) |
Fourth/subsequent | 70 (56.0) | 43 (59.7) | 12 (52.2) | 15 (50.0) |
Previous non-TNFi therapy, n (%) | ||||
Biological non-TNFi | ||||
Abatacept | 23 (18.4) | 22 (30.6) | 1 (4.4) | 0 (0.00) |
Rituximab | 7 (5.6) | 6 (8.3) | 0 (0.0) | 1 (3.3) |
Tocilizumab | 17 (13.6) | 16 (22.2) | 0 (0.0) | 1 (3.3) |
Sarilumab | 4 (3.2) | 4 (5.6) | 0 (0.0) | 0 (0.0) |
Secukinumab | 34 (27.2) | 0 (0.00) | 21 (91.3) | 13 (43.3) |
Ixekizumab | 3 (2.4) | 0 (0.0) | 0 (0.0) | 3 (10.0) |
Ustekinumab | 7 (5.6) | 0 (0.00) | 1 (4.4) | 6 (20.0) |
Targeted synthetic disease modifying antirheumatic drugs | ||||
Apremilast | 6 (4.8) | 0 (0.0) | 0 (0.0) | 6 (20.0) |
Baricitinib | 10 (8.0) | 10 (13.9) | 0 (0.0) | 0 (0.0) |
Tofacitinib | 14 (11.2) | 14 (19.4) | 0 (0.0) | 0 (0.0) |
TNFi previous to non-TNFi, n (%)* | 42 (42.4) | 17 (29.8) | 16 (76.2) | 9 (42.9) |